ReviewJournal of translational medicine2026

HER3 beyond the canonical paradigm: a versatile signaling hub in oncogenesis and therapeutic resistance.

Ying Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.